Global Non-melanoma Skin Cancer Market 2018-2022

非黒色腫皮膚癌の世界市場2018-2022

◆タイトル:Global Non-melanoma Skin Cancer Market 2018-2022
◆商品コード:IRTNTR23628
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年11月29日
◆ページ数:103
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥272,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥327,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、非黒色腫皮膚癌の世界市場について調査・分析し、市場概要、市場環境、非黒色腫皮膚癌市場規模、種類別(基底細胞癌、有棘細胞癌)分析、治療別分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・非黒色腫皮膚癌の世界市場概要
・非黒色腫皮膚癌の世界市場環境
・非黒色腫皮膚癌の世界市場動向
・非黒色腫皮膚癌の世界市場規模
・非黒色腫皮膚癌の世界市場:業界構造分析
・非黒色腫皮膚癌の世界市場:種類別(基底細胞癌、有棘細胞癌)
・非黒色腫皮膚癌の世界市場:治療別
・非黒色腫皮膚癌の世界市場:地域別市場規模・分析
・非黒色腫皮膚癌の北米市場規模・予測
・非黒色腫皮膚癌のヨーロッパ・中東・アフリカ市場規模・予測
・非黒色腫皮膚癌のアジア太平洋市場規模・予測
・非黒色腫皮膚癌の主要国分析
・非黒色腫皮膚癌の世界市場:意思決定フレームワーク
・非黒色腫皮膚癌の世界市場:成長要因、課題
・非黒色腫皮膚癌の世界市場:競争環境
・非黒色腫皮膚癌の世界市場:関連企業情報(ベンダー分析)

主な分析対象企業は、Bausch Health、F. Hoffmann-La Roche、Sun Pharmaceuticals、3M Pharmaceuticalsなどです。

About this market
Surgery is considered as the first line curative approach for NMSC, despite the presence of an extensive range of non-surgical treatment modalities. This is because surgery results in the highest cure rate. Surgical treatment provides superior outcomes regarding complete lesion response, clearance of NMSC, cumulative recurrence probabilities compared with cryotherapy, photodynamic therapy, radiotherapy, 5-FU, and imiquimod. Technavio’s analysts have predicted that the non-melanoma skin cancer market will register a CAGR of almost 6% by 2022.
Market Overview
Increase in incidence of NMSC
The white population in Europe, the US, and Australia are highly affected by NMSC, and the incidence of NMSC is increasing. Globally, NMSC differs significantly. Lower incidence rates are are registered in African countries and higher rates are observed in Australia. THE NMSC incidence rate is low in other parts of Europe compare to UK.
Few drugs in pipeline for NMSC
The drug pipeline for NMSC has very few molecules because of the low amount of R&D in this area. Non-disease modifying drugs are under evaluation. Most drugs are being evaluated for palliative care or as an adjuvant therapy. Various studies are being conducted to test newer targeted drugs for the treatment of advanced SCC.
For the detailed list of factors that will drive and challenge the growth of the non-melanoma skin cancer market during the 2018-2022, view our report.
Competitive Landscape
The market appears to be concentrated and with the presence of several companies including Bausch Health and F. Hoffmann-La Roche, the competitive environment is quite intense. Factors such as the increasing incidence of NMSC and NMSC coverage and support, will provide considerable growth opportunities to non-melanoma skin cancer manufactures. Bausch Health, F. Hoffmann-La Roche, Sun Pharmaceuticals, and 3M Pharmaceuticals are some of the major companies covered in this report.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: PIPELINE ANALYSIS
• NMSC pipeline
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• The threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: MARKET SEGMENTATION BY TYPE OF NMSC
• Segmentation by type of NMSC
• Comparison by type of NMSC
• BCC – Market size and forecast 2017-2022
• SCC – Market size and forecast 2017-2022
• Market opportunity by type of NMSC
PART 09: MARKET SEGMENTATION BY THERAPY
• Segmentation by therapy
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
• Geographical Segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 14: MARKET TRENDS
• Increasing incidence of NMSC
• Surgery considered as a first-line curative approach for NMSC
• High off-label use of topical treatments for NMSC
• Low physician adherence to NMSC diagnostic and treatment guidelines
PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bausch Health
• F. Hoffmann-La Roche
• Sun Pharmaceuticals
• 3M Pharmaceuticals
PART 17: APPENDIX
List of abbreviations

Exhibit 01: Global NMSC market
Exhibit 02: Global oncology market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2017
Exhibit 18: Type of NMSC – Market share 2017-2022 (%)
Exhibit 19: Comparison by type of NMSC
Exhibit 20: BCC – Market size and forecast 2017-2022 ($ mn)
Exhibit 21: BCC – Year-over-year growth 2018-2022 (%)
Exhibit 22: SCC – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: SCC – Year-over-year growth 2018-2022 (%)
Exhibit 24: Market opportunity by type of NMSC
Exhibit 25: Customer landscape
Exhibit 26: Global – Market share by geography 2017-2022 (%)
Exhibit 27: Regional comparison
Exhibit 28: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 29: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 30: Top 3 countries in Americas
Exhibit 31: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 32: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 33: Top 3 countries in EMEA
Exhibit 34: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 35: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 36: Top 3 countries in APAC
Exhibit 37: Market opportunity
Exhibit 38: Vendor landscape
Exhibit 39: Landscape disruption
Exhibit 40: Vendors covered
Exhibit 41: Vendor classification
Exhibit 42: Market positioning of vendors
Exhibit 43: Bausch Health – Overview
Exhibit 44: Bausch Health – Business segments
Exhibit 45: Bausch Health – Organizational developments
Exhibit 46: Bausch Health – Geographic focus
Exhibit 47: Bausch Health – Segment focus
Exhibit 48: Bausch Health – Key offerings
Exhibit 49: F. Hoffmann-La Roche – Overview
Exhibit 50: F. Hoffmann-La Roche – Business segments
Exhibit 51: F. Hoffmann-La Roche – Organizational developments
Exhibit 52: F. Hoffmann-La Roche – Geographic focus
Exhibit 53: F. Hoffmann-La Roche – Segment focus
Exhibit 54: F. Hoffmann-La Roche – Key offerings
Exhibit 55: Sun Pharmaceuticals – Overview
Exhibit 56: Sun Pharmaceuticals – Business segments
Exhibit 57: Sun Pharmaceuticals – Organizational developments
Exhibit 58: Sun Pharmaceuticals – Geographic focus
Exhibit 59: Sun Pharmaceuticals – Segment focus
Exhibit 60: Sun Pharmaceuticals – Key offerings
Exhibit 61: M Pharmaceuticals – Overview
Exhibit 62: M Pharmaceuticals – Business segments
Exhibit 63: M Pharmaceuticals – Organizational developments
Exhibit 64: M Pharmaceuticals – Geographic focus
Exhibit 65: M Pharmaceuticals – Segment focus
Exhibit 66: M Pharmaceuticals – Key offerings




【掲載企業】

Bausch Health、F. Hoffmann-La Roche、Sun Pharmaceuticals、3M Pharmaceuticals

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[非黒色腫皮膚癌の世界市場2018-2022]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆